Implications of Tecvayli Plus Darzalex Faspro Demonstrating 83% Reduction in Disease Progression or Death.

In an interview with Pharmaceutical Executive, Imran Khan, Md, PhD, Vice President of U.S. medical affairs for hematology, oncologist, Johnson & Johnson, discusseda new combination regimen for relapsed/refractory multiple myeloma, Tecvayli plus Darzalex Faspro.

Dr. Khan explains that the Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab) Phase III study in patients relapsing after one prior line of therapy showed an 83% reduction in risk of disease progression or death, with a hazard ratio of 0.17, which he describes as “nothing short of astounding.”

Over roughly three years of follow-up, many patients experienced no disease progression and no deaths, which he characterizes as transformational for a population with high unmet need. The regimen demonstrated consistent benefit across multiple endpoints, including response rates, MRD, overall survival, and symptom worsening, and led to a late-breaking oral presentation at ASH and supports a new standard of care.

He highlights the scientific rationale: combining Darzalex, a CD38-targeting monoclonal antibody, with Tecvayli, a BCMA-targeting bispecific that recruits T cells to kill myeloma cells. Both are highly active individually, but together they achieve synergistic efficacy without relying on traditional classes such as IMiDs and proteasome inhibitors. Safety is emphasized repeatedly; Johnson & Johnson implemented IVIG prophylaxis and aligned dosing schedules for both agents to reduce serious infections.